Eulav Asset Management Global Blood Therapeutics, Inc. Transaction History

Eulav Asset Management

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$22.3 - $37.39 $1 Million - $1.68 Million	-45,000 Reduced 10.59%	380,000 $12.1 Million
Q1 2022 May 10, 2022	SELL	$25.68 - $35.59 $1.93 Million - $2.67 Million	-75,000 Reduced 15.0%	425,000 $14.7 Million
Q4 2021 Feb 11, 2022	BUY	$24.9 - $40.26 $1.25 Million - $2.01 Million	50,000 Added 11.11%	500,000 $14.6 Million
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $1.02 Million - $1.49 Million	40,000 Added 9.76%	450,000 $11.5 Million
Q2 2021 Aug 06, 2021	BUY	$32.46 - $43.42 $2.11 Million - $2.82 Million	65,000 Added 18.84%	410,000 $14.4 Million
Q1 2021 Apr 30, 2021	BUY	$38.94 - $50.85 $973,500 - $1.27 Million	25,000 Added 7.81%	345,000 $14.1 Million
Q4 2020 Feb 16, 2021	BUY	$37.65 - $63.77 $12 Million - $20.4 Million	320,000 New	320,000 $13.9 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

Stay updated on Eulav Asset Management with notifications on news.